Eisele Jeffrey's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Jan 31, 2024
- Accession no.
- 0001127602-24-002738
- Filed
- Jan 31, 2024
- Trade date
- Jan 29-30, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $81.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Eisele JeffreyCIK 0001827326 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2024 | Common Stock | SSaleDisposed | −279 | $64.14 | −$17,895.06 | 58,179 | Direct | |
| Jan 30, 2024 | Common Stock | SSaleDisposed | −971 | $65.53 | −$63,629.63 | 57,208 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.